Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

AMSTERDAM, Niederlande, und OSAKA, Japan, 11. September 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) gab heute die Ergebnisse der Studie zur kardiovaskulären Sicherheit EXAMINE bekannt. EXAMINE steht für EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE (Vergleich des kardiovaskulären Outcomes – Alogliptin vs. Standardtherapie). Die Studie wurde bei Patienten mit Typ 2 Diabetes, die bereits ein akutes Koronarsyndrom hinter sich hatten, durchgeführt, die auf Basis einer Standardtherapie entweder Alogliptin oder Placebo erhielten. Es konnte gezeigt werden, dass das Risiko für ein kardiovaskuläres Ereignis in beiden Gruppen vergleichbar war. Damit konnte die Anforderung der „Non-Inferiority" („Nicht-Unterlegenheit") für Alogliptin erfüllt werden. Der primäre Endpunkt der Nichtinferiorität gegenüber Placebo auf Basis der Standardtherapie bei einer Patientenpopulation mit Diabetes Typ 2 und erhöhtem Risiko für ein kardiovaskuläres Ereignis wurde erreicht. Diese im New England Journal of Medicine (NEJM) veröffentlichten und auf dem ESC Congress 2013 vorgestellten Daten belegen, dass Alogliptin das kardiovaskuläre Risiko von Patienten mit Diabetes Typ 2, bei denen aufgrund eines kurz zuvor aufgetretenen akuten Koronarsyndroms (ACS) ein hohes Risiko für ein schwerwiegendes kardiovaskuläres Ereignis (major adverse cardiovascular event,  MACE) besteht, nicht erhöht. Der primäre Endpunkt bestand aus folgenden Komponenten: kardiovaskulär bedingter Tod, nicht tödlicher Herzinfarkt, nicht tödlicher Schlaganfall. Der primäre Endpunkt trat in der Alogliptin und in der Placebo-Gruppe mit ähnlicher Häufigkeit auf: bei 11,3 % der Patienten der Alogliptin-Gruppe bzw. bei 11,8 % der Patienten der Placebogruppe
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... YORK, Sept. 23 Reportlinker.com announces that a ... catalogue: Genzyme Corporation: PharmaVitae Profile ... Introduction This analysis examines the historical ... pharmaceutical sector. The profile encompasses global company strategy, ...
... Calif., Sept. 23 Preclinical data of a ... blood pressure) was presented Tuesday, September 21st, at ... Washington, DC, by Christopher D. Owens, MD, MSc, ... Endovascular Surgery, University of California, San Francisco. The ...
Cached Medicine Technology:Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 2Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 3Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 4Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 5Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 6Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 7Promising New Therapy for Drug-Resistant Hypertension Presented at Interventional Cardiology Meeting in Washington, D.C. 2
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare have ... of Shriners Hospitals for Children - Lexington from 1900 ... of Kentucky Albert B. Chandler Hospital. The new facility ... operated by Shriners Hospitals for Children, and designed to ... families well into the future. , “The quality care ...
(Date:10/22/2014)... October 22, 2014 Best Cheap Hosting ... the world. The site has recently announced that iPower ... supplier for people from around the world. , “iPower ... operation today and is providing various kinds of useful ... company insists on offering excellent customer service and a ...
(Date:10/22/2014)... PA (PRWEB) October 22, 2014 Richard ... as an industry leader with over 25 years experience. ... team leader in the areas related to EDI, B2B ... Carlson is an Editorial Advisory Board member for Pharmaceutical ... Educator. Blue Fin Group is a management and ...
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The newly ... must-have source of thousands of facts, figures and forecasts ... and 68 medical sector forecast categories the Worldwide ... global, regional and national views on the worldwide medical ... , The report gives you data for 2010-2019, covering ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... Arthritis is the nation,s most common cause of ... projected to increase to 67 million by 2030, and ... activity as a result, according to the Centers for ... University of Missouri researchers found that adults with arthritis ...
... 8 Accuray,Incorporated (Nasdaq: ARAY ), a global ... first CyberKnife(R) Robotic Radiosurgery System in,the Kingdom of Saudi ... Hospital and Research Center in Riyadh. It is the ... region., King Faisal Specialist Hospital, the leading medical ...
... ... Industry, PORTLAND, Maine, Oct. ... drugs for pets, reports that,the current Bear market will not hamper its ... owners are committed to their pet,s welfare and want the same,standard of ...
... Weight Watchers,International, Inc. (NYSE: WTW ) today ... as its President, North America, effective November,3, 2008. ... and general management experience, will oversee the Company,s,North ... and licensing businesses and will be reporting to ...
... or "the Company") (OTC Bulletin Board: SOBM) is ... on October 2, 2008 to officially,appoint Lionel Choong ... Consulting Services Agreement to be effective as of ... appointed to the Company,s audit,committee. An earlier news ...
... FRANCISCO, Oct. 8 Dr. Jane Hightower -- widely,acknowledged ... in patients who regularly consume certain types of fish ... failed to inform and protect,the public from the risks ... seafood. Dr. Hightower has released a new book, Diagnosis:,Mercury: ...
Cached Medicine News:Health News:Incorporating education in exercise programs increases benefits for arthritis patients 2Health News:First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center 2Health News:First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center 3Health News:First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center 4Health News:Maine Company/Startup Undaunted by Bear Market 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Sinobiomed Directors Confirm Hiring of New Chief Financial Officer 2Health News:New Evidence Highlights Dangers of Mercury Toxicity in Fish 2
Full-Height Radiation Barriers provide full-body shielding and reduce eye strain during extended procedures....
RayShield Frame Mounted Overhead Lead Acrylic Barriers are offered in a choice of three sizes: 60 cm x 80 cm ( 24" x 32") wide, 60 cm x 50 cm( 24" x 20") wide. Lead acrylic windows of 0.5 mm and 1.0 ...
... prevent lower body exposure to scattered radiation. Dual ... where X-ray fluoroscopy is used. These shields are ... C-arm fluoroscopy units are used. Three sizes of ... with a 17 cm wide mounting bracket that ...
Pregnancy Apron...
Medicine Products: